FDA to Expand High Performance Computing to Boost Clinical Trial Efficiency

Drug Industry Daily
The FDA plans to expand its capabilities in high performance computing to help build disease models and simulate clinical trials — as well as establish a new framework for regenerative medicine this fall — as part of an agency “innovation initiative” announced Friday by Commissioner Scott Gottlieb.

To View This Article:


Subscribe To Drug Industry Daily